Shedding Light on Extracellular Vesicle Biogenesis and Bioengineering.

Teng F, Fussenegger M. · 2020

Read Shedding Light on Extracellular Vesicle Biogenesis and Bioengineering. by Teng F, Fussenegger M. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7788585.txt.

Introduction

Teng and Fussenegger review how extracellular vesicles form and how they can be engineered. These vesicles are tiny sacs that cells release. They carry proteins, RNAs, DNAs, lipids, and metabolites. Cells that take them up can change behavior.

Vesicles cause little immune reaction. That trait makes them strong candidates for drug delivery. The authors sum up recent gains in vesicle biology. They then cover new engineering strategies. Vesicles can be loaded or tuned to carry cargo to chosen cells. The review weighs the path toward clinical use. It also names the hurdles that still block bioengineered vesicles in medicine.

Catalog record

CREATORTeng F, Fussenegger M.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE105 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7788585

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Shedding Light on Extracellular Vesicle Biogenesis and Bioengineering By Fei Teng, Martin Fussenegger Published in: Advanced Science DOI: 10.1002/advs.202003505 ABSTRACT Abstract Extracellular vesicles (EVs) are biocompatible, nano‐sized secreted vesicles containing many types of biomolecules, including proteins, RNAs, DNAs, lipids, and metabolites. Their low immunogenicity and ability to functionally modify recipient cells by transferring diverse bioactive constituents make them an excellent candidate for a next‐generation drug delivery system. Here, the recent advances in EV biology and emerging strategies of EV bioengineering are summarized, and the prospects for clinical translation of bioengineered EVs and the challenges to be overcome are discussed. INTRODUCTION Extracellular vesicles (EVs) are heterogeneous nano‐sized membrane vesicles that are released from various cell types.[ 1 ] Classically, there are three major subtypes of EVs defined on the basis of their biological pathways, i.e., exosomes, microvesicles, and apoptotic bodies.[ 1 , 2 , 3 , 4 , 5 , 6 , 7 ] Exosomes are vesicles formed by inward invagination of the endosomal membrane and fusion of the multivesicular body (MVB) with the plasma membrane. Microvesicles are formed by direct outward budding from the plasma membrane of healthy cells. Apoptotic bodies are formed during apoptosis by outward blebbing of the plasma membrane of cells. With the advance of EV studies, diverse EV subtypes have been proposed, using terms such as ectosomes, microparticles, oncosomes, etc., in addition to the three major types mentioned above.[ 7 , 8 ] The different terminologies based on function, biogenesis, size or cell of origin, as well as the variety of isolation methods and contexts, and the paucity of validated biomarkers, have led to various misconceptions and even contradictory definitions in the literature.[ 7 , 10 ] In this context, the International Society for Extracellular Vesicles (ISEV) has proposed the term “extracellular vesicle” as generic nomenclature for cell‐released vesicles, and has also recommended minimal requirements for EV studies.[ 7 , 11 ] In addition, the EV‐TRACK platform has been launched to facilitate standardization of EV research through more systematic reporting of EV biology and methodology.[ 9 ] In this review, we will use EVs as a generic term for the entire population of vesicles secreted from cells, since most research described in the literature has utilized heterogeneous populations of EVs, and often failed to characterize the isolated EVs in detail.[ 7,8 ] EVs were originally discovered by Clargaff and West in 1946 as procoagulant platelet‐derived particles in normal plasma.[ 12 ] Since then, the biology and functions of EVs have been widely investigated (for example, see refs. [13, 14] reviewed in refs. [1, 15]). In 1983, EVs derived from fusion of MVBs with the plasma membrane of reticulocytes were observed.[ 16 , 17 ] Subsequently, EVs were implicated in immune regulation[ 18 , 19 ] and transfer of genetic materials,[ 20 , 21 , 22 ] highlighting their role in cell–cell communication. It has been established that EVs contain thousands of different biomolecules, including proteins, RNAs, DNAs, lipids, and metabolites,[ 5 , 23 , 24 ] and are highly heterogeneous in terms of their size, content, functional impacts on recipient cells, and cell of origin.[ 15 , 25 ] Here, we focus mainly on the most extensively studied EVs, typically designated as exosomes and microvesicles (ectosomes), which play key roles in intercellular communication by delivering signals to recipient cells.[ 26 , 27 ] These EVs hold great promise for developing next‐generation delivery vehicles for therapeutic agents. EV BIOGENESIS AND SECRETION EVs are formed through multiple mechanisms (Figure 1 ). Classically, exosome biogenesis is initiated from the endosomal pathway, i.e., the formation of early endosomes via invagination of the plasma membrane. In some cases, vesicles derived from the budding of the trans‐Golgi network (TGN) can fuse with early endosomes.[ 25 , 28 ] During the following maturation process, early endosomes fuse to form late endosomes, leading to invagination of the endosomal membrane into the lumen and form intraluminal vesicles (ILVs). This in turn leads to the formation of multivesicular endosomes or MVBs with a characteristic multivesicular appearance. MVBs ultimately fuse with the plasma membrane and release the ILVs into the extracellular milieu in the form of exosomes. Alternatively, MVBs can fuse with lysosomes/autophagosomes to be degraded.[ 5 , 25 ] Briefly, the generation of exosomes consists of three steps: biogenesis, transport and release. Microvesicles (MVs) are derived from the plasma membrane by direct outward budding and fission, which is reminiscent of a reverse version of endocytosis.[ 5 , 27 ] [Figure: Biogenesis and secretion of EVs. Two mechanisms of EV biogenesis are illustrated. The process of releasing exosomes into the extracellular milieu contains three distinct steps: exosome biogenesis, intracellular trafficking of MVBs, and fusion of MVBs with the plasma membrane. Early endosomes are formed by the inward budding of the plasma membrane (Step 1a1), or in some cases from the trans‐Golgi network (TGN) (Step 1a2). Early endosomes mature into late endosomes (Step 1b) and finally generate MVBs, in which process ILVs are formed by inward invagination of the endosome limiting membrane (Step 2). The fate of MVBs can be fusion with the plasma membrane (Step 3a1), which results in the release of exosomes (Step 3a2). Alternatively, MVBs can fuse with lysosomes/autophagosomes for degradation (Step 3b1, 2). Several molecules are involved in the biogenesis (e.g., RABs, ESCRTs, syndecan, ceramide, tetraspanins, etc.), trafficking (e.g., RABs, actin, etc.), and fusion of MVBs with the plasma membrane (e.g., SNAREs). Microvesicles arise from the direct outward budding and fission of the plasma membrane. Several molecules are involved in the biogenesis and release of microvesicles (small GTPases, ESCRTs, ARRDC1, etc.). Abbreviations: EV, extracellular vesicle; ESCRT, endosome sorting complex required for transport; MVB, multivesicular body; ILV, intraluminal vesicle; RAB, RAS‐related protein; ALIX, ALG‐2 interacting protein X; nSMase2, neutral sphingomyelinase 2; Ral‐1, RAL (Ras‐related GTPase) homolog; SNARE, soluble NSF attachment protein receptor; VAMP7, vesicle‐associated membrane protein 7; SNAP23, synaptosomal‐associated protein 23; Syx1A, syntaxin 1A; ARF, ADP ribosylation factor; RohA, Ras homolog family member A; A‐SMase, acid sphingomyelinase; ARRDC1, arrestin domain containing protein 1. *, homologs in C. elegans.] MVB Biogenesis The endosome sorting complexes required for transport (ESCRT) machinery plays an important role in the formation of MVBs and ILVs (Figure 1). The ESCRTs comprise four distinct complexes (ESCRT‐0, ‐I, ‐II, and ‐III) and the accessory Vps4 complex, with each of them consisting of several subunits (Box 1 ) (reviewed in refs. [29, 30, 31]). Box 1The endosomal sorting complexes required for transport (ESCRT) machinery was originally identified in budding yeast through genetic and biochemical characterization of vacuolar protein sorting (vps) mutants.[ 173 ] ESCRT complexes have been extensively studied in yeast and human, and comprise ESCRT‐0, ESCRT‐I, ESCRT‐II, ESCRT‐III subcomplexes and ATPase complex, as well as several accessory proteins (see Table). Among them, ESCRT‐0, ESCRT‐I, ESCRT‐II and ATPase complex are stable complexes existing before recruitment,[ 38 , 50 , 173 , 251 ] while ESCRT‐III subunits are dynamically assembled after recruitment.[ 51 , 53 ] The ESCRT machinery plays a vital role in a series of membrane remodeling events, including multivesicular body (MVB) biogenesis, cytokinetic abscission and viral budding.[ 252 , 253 ] The table lists the main components involved in the ESCRT pathway.[ 29 , 31 , 252 , 254 , 255 ]

Read the complete text